Stoke Therapeutics, Inc. $STOK Stock Holdings Lowered by Charles Schwab Investment Management Inc.

Key Points

• Charles Schwab Investment Management Inc. reduced its stake in Stoke Therapeutics by 9.3%, downsizing to 310,307 shares after selling 31,822 shares in the first quarter.
• Stoke Therapeutics reported earnings of ($0.40) EPS, outperforming expectations by $0.17, but its revenue of $13.82 million fell short of analyst estimates of $31.51 million.
• Research analysts are generally optimistic about Stoke Therapeutics, with a consensus rating of "Buy" and a target price of $25.57, while the stock is currently trading at $19.76.

Charles Schwab Investment Management Inc. reduced its stake in shares of Stoke Therapeutics, Inc. (NASDAQ:STOK - Free Report) by 9.3% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 310,307 shares of the company's stock after selling 31,822 shares during the period. Charles Schwab Investment Management Inc. owned 0.57% of Stoke Therapeutics worth $2,064,000 as of its most recent SEC filing.

Several other large investors have also modified their holdings of STOK. GAMMA Investing LLC raised its holdings in Stoke Therapeutics by 1,842.0% in the first quarter. GAMMA Investing LLC now owns 5,360 shares of the company's stock valued at $36,000 after buying an additional 5,084 shares during the period. US Bancorp DE raised its holdings in Stoke Therapeutics by 9,743.9% in the first quarter. US Bancorp DE now owns 11,222 shares of the company's stock valued at $75,000 after buying an additional 11,108 shares during the period. Tower Research Capital LLC TRC raised its holdings in Stoke Therapeutics by 70.1% in the fourth quarter. Tower Research Capital LLC TRC now owns 11,930 shares of the company's stock valued at $132,000 after buying an additional 4,918 shares during the period. Invesco Ltd. acquired a new stake in Stoke Therapeutics in the fourth quarter valued at approximately $133,000. Finally, ProShare Advisors LLC acquired a new stake in Stoke Therapeutics in the fourth quarter valued at approximately $139,000.

Wall Street Analyst Weigh In

Several analysts have issued reports on STOK shares. Cantor Fitzgerald raised shares of Stoke Therapeutics to a "strong-buy" rating in a research report on Wednesday, May 14th. Chardan Capital reaffirmed a "buy" rating and issued a $24.00 price objective on shares of Stoke Therapeutics in a research report on Wednesday, August 13th. Wedbush increased their price objective on shares of Stoke Therapeutics from $16.00 to $22.00 and gave the company an "outperform" rating in a research report on Wednesday, August 13th. Needham & Company LLC reaffirmed a "buy" rating and issued a $22.00 price objective on shares of Stoke Therapeutics in a research report on Tuesday, July 1st. Finally, BTIG Research set a $28.00 price objective on shares of Stoke Therapeutics and gave the company a "buy" rating in a research report on Monday, August 18th. Two analysts have rated the stock with a Strong Buy rating and seven have issued a Buy rating to the company's stock. Based on data from MarketBeat, the stock currently has an average rating of "Buy" and an average price target of $25.57.

Stoke Therapeutics Stock Up 0.9%

STOK stock traded up $0.18 during trading on Wednesday, hitting $19.77. 1,287,856 shares of the company's stock traded hands, compared to its average volume of 810,398. Stoke Therapeutics, Inc. has a 52 week low of $5.35 and a 52 week high of $20.45. The stock has a fifty day moving average price of $14.42 and a two-hundred day moving average price of $10.83. The stock has a market capitalization of $1.08 billion, a price-to-earnings ratio of 23.26 and a beta of 1.14.

Stoke Therapeutics (NASDAQ:STOK - Get Free Report) last released its earnings results on Tuesday, August 12th. The company reported ($0.40) earnings per share for the quarter, beating the consensus estimate of ($0.57) by $0.17. Stoke Therapeutics had a net margin of 26.25% and a return on equity of 18.32%. The firm had revenue of $13.82 million during the quarter, compared to analyst estimates of $31.51 million. As a group, equities research analysts expect that Stoke Therapeutics, Inc. will post -2.01 EPS for the current fiscal year.

Insider Buying and Selling at Stoke Therapeutics

In other Stoke Therapeutics news, General Counsel Jonathan Allan sold 13,712 shares of the business's stock in a transaction on Wednesday, August 13th. The shares were sold at an average price of $15.00, for a total transaction of $205,680.00. Following the completion of the sale, the general counsel owned 19,631 shares in the company, valued at $294,465. The trade was a 41.12% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Barry Ticho sold 4,504 shares of the company's stock in a transaction dated Friday, August 1st. The stock was sold at an average price of $12.82, for a total transaction of $57,741.28. Following the transaction, the insider owned 16,775 shares of the company's stock, valued at $215,055.50. This represents a 21.17% decrease in their position. The disclosure for this sale can be found here. 9.50% of the stock is owned by insiders.

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.